Abstract
Isocitrate dehydrogenase (IDH) is a metabolic enzyme that converts isocitrate to α-ketoglutarate (α-KG). Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia. After treatment with AG-221 in clinical trials, a first-in-class inhibitor of mutated IDH2, 29 patients with acute myeloid leukemia or myelodysplastic syndrome experience complete remissions and the overall response rate is 59/159 (37%). Thus, IDH mutants have become intriguing targets for cancer therapeutics. In addition to providing a brief summary of IDH mutations, this review describes known inhibitors with potential activities against IDH mutants such as AG-120, AG-221, AG-881 and AGI-6780. The evolving landscape of IDH mutant inhibitors provides us an outlook on the discovery of novel, safer, and more effective cancer treatment strategies.
Keywords: Cancer, drug discovery, IDH1, IDH2, inhibitor, mutant.
Mini-Reviews in Medicinal Chemistry
Title:The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Volume: 16 Issue: 16
Author(s): Jiao Chen, Jie Yang and Peng Cao
Affiliation:
Keywords: Cancer, drug discovery, IDH1, IDH2, inhibitor, mutant.
Abstract: Isocitrate dehydrogenase (IDH) is a metabolic enzyme that converts isocitrate to α-ketoglutarate (α-KG). Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia. After treatment with AG-221 in clinical trials, a first-in-class inhibitor of mutated IDH2, 29 patients with acute myeloid leukemia or myelodysplastic syndrome experience complete remissions and the overall response rate is 59/159 (37%). Thus, IDH mutants have become intriguing targets for cancer therapeutics. In addition to providing a brief summary of IDH mutations, this review describes known inhibitors with potential activities against IDH mutants such as AG-120, AG-221, AG-881 and AGI-6780. The evolving landscape of IDH mutant inhibitors provides us an outlook on the discovery of novel, safer, and more effective cancer treatment strategies.
Export Options
About this article
Cite this article as:
Chen Jiao, Yang Jie and Cao Peng, The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors, Mini-Reviews in Medicinal Chemistry 2016; 16 (16) . https://dx.doi.org/10.2174/1389557516666160609085520
DOI https://dx.doi.org/10.2174/1389557516666160609085520 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Mini-Reviews in Medicinal Chemistry A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade
Current Medicinal Chemistry Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets